Skip to content
value.today

Trinity Biotech PLC: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

The market value here is from Aug 1, 2026, more than 60 days ago: no market-data feed is connected for this exchange yet, so read the comparisons with today's price with that in mind.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Diagnostics and Research: $145 M to $492 M, median $330 M$0 M$133 M$266 M$398 M$531 MMarket value $8 M

Your own DCF model

A full discounted-cash-flow model of Trinity Biotech PLC, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Diagnostics and Research

Multiples of its companies with a market value at most 60 days old, times Trinity Biotech PLC's own figures of FY2024.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Trinity Biotech PLCApplied toValue (25th to 75th)Companies
Price to sales2.4× / 5.4× / 8.0×0.1×revenue $62 M$145 M to $492 M37

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Trinity Biotech PLC's multiples at each month end with a market cap on file, Jan 2020 to Aug 2026, each against its own median.

Price to sales

0.1×

Now below its median of 3.8×, in the bottom quarter of its range; range 0.1× to 5.9× over 20 months.

0×1×3×4×6×2020202120222023202420252026Price to sales 0×Median 4×

as of Aug 1, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Aug 1, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2024to Dec 31, 2024$62 M$-32 M$-4 M$0 M$-5 M$-5 MSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$57 M$-24 M$-12 M$1 M$-12 M$-3 MSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$63 M$-41 M$-1 M$1 M$-2 M$-6 MSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$81 M$1 M$13 M$2 M$11 M$57 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$102 M$-6 M$24 M$3 M$21 M$55 MSEC annual report (10-K, 20-F)
FY2019to Dec 31, 2019$90 M$-29 M$5 M$2 M$3 M$67 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $8 M on Aug 1, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.